PlainRecalls
CriticalClass IOngoing

FDA Drug recall · Reported March 11, 2026

MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil

Recall #
D-0397-2026
Affected scope
4
Initiated
December 15, 2025
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

StuffbyNainax recalled MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7 - a critical-severity action.

MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7 was recalled by StuffbyNainax in March 11, 2026. Reason: Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadala…. Check the official notice for the remedy. Verify recall #D-0397-2026 with the FDA Drug before acting.

The recall

StuffbyNainax issued this critical-severity FDA Drug recall-Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadala….

Critical
severity level
4 units
affected scope
Class I
classification
March 11, 2026
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-0397-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-0397-2026) was formally reported on March 11, 2026, with the manufacturer initiating the action on December 15, 2025. It is classified under Critical severity (Class I), with a current status of Ongoing. StuffbyNainax is listed as the recalling firm, operating out of Huntsville, TX. Federal records list the affected scope as 4.

The documented reason for this recall is: Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil Distribution data in the federal record shows the product reached: Product was distributed to 4 customers in the US.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Critical

Affected scope

4

Related Recalls

6

5 from same agency

Product description

MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7

Reason for recall

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Critical (Class I)
Status Ongoing
Recall number D-0397-2026
Date reported March 11, 2026
Date initiated December 15, 2025
Recalling firm StuffbyNainax
Firm location Huntsville, TX
Affected scope 4
Distribution Product was distributed to 4 customers in the US.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

Scale of Impact

4 units affected - limited or regional distribution scale.

Regional (<10K units) ✓ This recall
Multi-state (10K – 100K units) -
Large-scale (100K – 1M units) -
Massive (≥1M units) -

Bracket cutoffs follow federal recall-disclosure conventions; bar widths scale linearly within each bracket. Source: PlainRecalls analysis of U.S. Food and Drug Administration filings.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-0397-2026) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • This is a Class I (high-risk) recall, stop using the product immediately and follow the disposal or return instructions. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7. Recalled by StuffbyNainax. Units affected: 4.
Why was this product recalled?
Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil
Which agency issued this recall?
This recall was issued by the FDA Drug on March 11, 2026. Severity: Critical. Recall number: D-0397-2026.
Where was the recalled product distributed?
Distribution: Product was distributed to 4 customers in the US..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-0397-2026) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 11, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.